Long-term outcome of adenosine A2A receptor antagonist on lower urinary tract symptoms in male Parkinson disease patients
T Kitta, I Yabe, Y Kanno, M Higuchi… - Clinical …, 2018 - journals.lww.com
Objectives In addition to motor symptoms, bladder dysfunction is a major clinical issue in
patients with Parkinson disease (PD). Istradefylline is adenosine A2A receptor antagonist
approved for PD patients with wearing-off symptoms. The aim of this study was to determine
the long-term effects of istradefylline on lower urinary tract symptoms (LUTSs) in PD patients.
Methods We enrolled 14 male PD patients. The mean age of patients was 73 years (61–77
years), the Hoehn-Yahr stage was 2 (2–3), and disease duration was 9 years (3–28 years) …
patients with Parkinson disease (PD). Istradefylline is adenosine A2A receptor antagonist
approved for PD patients with wearing-off symptoms. The aim of this study was to determine
the long-term effects of istradefylline on lower urinary tract symptoms (LUTSs) in PD patients.
Methods We enrolled 14 male PD patients. The mean age of patients was 73 years (61–77
years), the Hoehn-Yahr stage was 2 (2–3), and disease duration was 9 years (3–28 years) …
